Case Type: Mergers & Acquisitions

We are investigating the Board of Directors of Avenue Therapeutics, Inc. (“Avenue” or the “Company”) (NasdaqCM: ATXI) for possible breaches of fiduciary duty related to the sale of the company to InvaGen Pharmaceuticals, Inc. and Madison Pharmaceuticals, Inc. Under the terms of the proposed transaction, Avenue shareholders are only anticipated to receive $13.92 for each … Read more

We are investigating the Board of Directors of Dominion Energy Midstream Partners, LP (“Dominion Energy Midstream” or the “Company”) (NYSE: DM) for possible breaches of fiduciary duty related to the sale of the company to Dominion Energy, Inc. Under the terms of the proposed transaction, Dominion Energy Midstream shareholders are only anticipated to receive 0.2492 … Read more

We are investigating the Board of Directors of Pacific Biosciences of California, Inc. (“PACB” or the “Company”) (NasdaqGS: PACB) for possible breaches of fiduciary duty related to the sale of the company to Illumnia, Inc. Under the terms of the proposed transaction, PACB shareholders are only anticipated to receive $8.00 in cash for each share … Read more

We are investigating the Board of Directors of WildHorse Resource Development Corporation (“WildHorse” or the “Company”) (NYSE: WRD) for possible breaches of fiduciary duty related to the sale of the company to Chesapeake Energy Corporation (“Chesapeake”). Under the terms of the proposed transaction, WildHorse shareholders are only anticipated to receive 5.989 shares of Chesapeake common … Read more

We are investigating the Board of Directors and Officers of TESARO, Inc. (“Tesaro” or the “Company”) (NasdaqGS: TSRO) for possible breaches of fiduciary duty.

We are investigating the Board of Directors of ARRIS International plc (“ARRIS” or the “Company”) (NasdaqGS:ARRS) for possible breaches of fiduciary duty related to the sale of the company to CommScope Holding Company, Inc. Under the terms of the proposed transaction, ARRIS shareholders are only anticipated to receive $31.75 for each share of ARRIS common … Read more

We are investigating the Board of Directors of Electro Scientific Industries, Inc. (“ESI” or the “Company”) (NasdaqGS:ESIO) for possible breaches of fiduciary duty related to the sale of the company to MKS Instruments, Inc. (MKSI). Under the terms of the proposed transaction, shareholders of ESI will receive only $30.00 in cash for each share of … Read more

We are investigating Resolute Energy (“Resolute Energy” or the “Company”) (NYSE: REN) relating to the sale of the Company to Cimarex Energy Co. (“Cimarex”). As a result of the merger, Resolute shareholders are only anticipated to receive either receive either $35 in cash per share or a combination of $14 and 0.2366 shares of Cimarex.

We are investigating National Commerce Corp. (“NCOM” or the “Company”) (NasdaqGS: NCOM) relating to the sale of the Company to CenterState Bank. As a result of the merger, NCOM shareholders are only anticipated to receive $40.01 per share.

We are investigating iPass Inc. (“iPass” or the “Company”) (NasdaqCM: IPAS) relating to the sale of the Company to Pareteum Corporation (“Pareteum”). As a result of the merger, iPass shareholders are only anticipated to receive 1.17 shares of Pareteum for each share of iPass stock owned.